Want to see HK:9877 full AI Analyst Report?
Top Page
Jenscare Scientific Co. Ltd. Class H
(9877)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$7.50
▲(1.35% Upside)
Action:Reiterated
Date:09/27/26
The score is held back primarily by ongoing heavy losses and negative free cash flow, indicating the business is not yet financially self-sustaining despite improved revenue and strong gross margins. Low leverage supports balance-sheet resilience, while technicals are mixed (near-term stabilization but weaker longer-term trend). Valuation is difficult to assess with a negative P/E and no dividend yield data.
Positive Factors
Revenue ramp and gross margin
The sharp revenue ramp indicates that Jenscare has moved beyond development toward commercial adoption of its structural heart products. A gross margin near 75% also suggests attractive product economics, providing potential operating leverage as sales expand and the installed commercial base grows.
Negative Factors
Deep net losses
The scale of current losses relative to the 2025 revenue base shows that Jenscare has not established earnings power yet. Persistent losses can consume accumulated capital, delay self-funding, and make the company dependent on continued commercialization progress before shareholders see sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue ramp and gross margin
The sharp revenue ramp indicates that Jenscare has moved beyond development toward commercial adoption of its structural heart products. A gross margin near 75% also suggests attractive product economics, providing potential operating leverage as sales expand and the installed commercial base grows.
Read all positive factors
Jenscare Scientific Co. Ltd. Class H (9877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.22B
Dividend YieldN/A
Average Volume (3M)16.50K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth992.68%
EPS Growth35.04%
CountryHK
Employees225
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-0.34
Shares Outstanding310,306,200
10 Day Avg. Volume13,280
30 Day Avg. Volume16,498
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.22
Price to Sales (P/S)37.79
P/FCF Ratio-41.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)HK$261.02M
Jenscare Scientific Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Jenscare Scientific Co., Ltd. operates as a medical technology enterprise dedicated to advancing interventional therapies for structural heart conditions within the People's Republic of China. Among its pipeline, the company features LuX-Valve, an...
How the Company Makes Money
The company primarily makes money by selling its medical devices and associated procedural systems to healthcare providers and/or through distribution channels, generating revenue per unit sold (and, where applicable, per procedure supported by it...
Jenscare Scientific Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 140.08M | 88.24M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 107.15M | 66.60M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -43.41M | -209.85M | 12.63M | -426.40M | -502.08M | -498.58M |
| Net Income | -148.71M | -264.21M | -177.51K | -371.74M | -439.31M | -500.52M |
Balance Sheet | ||||||
| Total Assets | 841.53M | 896.62M | 1.03B | 1.33B | 1.43B | 1.34B |
| Cash, Cash Equivalents and Short-Term Investments | 414.54M | 527.63M | 605.99M | 1.09B | 825.11M | 800.59M |
| Total Debt | 39.68M | 47.38M | 64.42M | 44.08M | 3.87M | 2.41M |
| Total Liabilities | 107.46M | 123.16M | 110.61M | 100.84M | 58.30M | 50.77M |
| Stockholders Equity | 750.42M | 789.75M | 931.76M | 1.23B | 1.37B | 1.29B |
Cash Flow | ||||||
| Free Cash Flow | -73.92M | -80.08M | -288.81M | -300.64M | -208.03M | -157.25M |
| Operating Cash Flow | -61.17M | -75.00M | -217.55M | -222.44M | -158.48M | -141.89M |
| Investing Cash Flow | 6.87M | 5.96M | 5.59M | 358.13M | -146.58M | -475.07M |
| Financing Cash Flow | -22.10M | -20.61M | -110.74M | 56.44M | 188.93M | 1.08B |
Jenscare Scientific Co. Ltd. Class H Technical Analysis
Negative
7.40
Price Trends
7.28
Negative
7.46
Negative
8.16
Negative
Market Momentum
0.02
Negative
48.54
Neutral
69.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9877, the sentiment is Negative. The current price of 7.4 is above the 20-day moving average (MA) of 7.29, above the 50-day MA of 7.28, and below the 200-day MA of 8.16, indicating a bearish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 48.54 is Neutral, neither overbought nor oversold. The STOCH value of 69.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9877.
Jenscare Scientific Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.25B | 11.90 | 13.24% | 2.49% | 16.15% | 31.89% | |
61 Neutral | HK$7.02B | 23.77 | 9.64% | 0.79% | 34.94% | 12.99% | |
59 Neutral | HK$5.64B | 88.11 | 1.71% | ― | 0.75% | -20.22% | |
59 Neutral | HK$2.94B | 29.10 | 4.08% | ― | 94.80% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$4.22B | -18.26 | -19.31% | ― | 992.68% | 35.04% | |
48 Neutral | HK$3.30B | -18.49 | -7.65% | ― | 21.23% | 36.89% |
* Healthcare Sector Average
HK:9877
Jenscare Scientific Co. Ltd. Class H
7.27
-3.55
-32.81%
HK:9996
Peijia Medical Ltd.
4.58
-1.92
-29.51%
HK:1302
LifeTech Scientific Corporation
1.31
-0.83
-38.79%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
32.84
2.14
6.98%
HK:1789
AK Medical Holdings Ltd.
4.74
-0.70
-12.86%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
6.99
-1.05
-13.06%
Jenscare Scientific Co. Ltd. Class H Corporate Events
Jenscare Wins NMPA Approval for JensClip, Accelerates Global Valve Portfolio Push
Sep 22, 2026
Jenscare Scientific has received registration approval from China’s National Medical Products Administration for its JensClip Transcatheter Mitral Valve Repair Clip System. The device features an innovative self-locking design, flexible shap...
Jenscare Wins Hong Kong Approval for LuX-Valve Plus Valve System
Sep 4, 2026
Jenscare Scientific Co., Ltd., a China-based structural heart medical device maker, focuses on transvenous valve replacement systems such as LuX-Valve Plus for treating tricuspid regurgitation. The company targets major cardiovascular markets in E...
Jenscare Raises Caps on Connected Medical Device Accessories Deal
Aug 31, 2026
Jenscare Scientific has revised the annual caps under its Medical Devices Accessories Purchase Agreement with Linstant, a related party ultimately controlled by a substantial shareholder, after actual and expected transaction amounts were projecte...
Jenscare Scientific Delivers Strong Interim Growth as Structural Heart Portfolio Globalizes
Aug 31, 2026
Jenscare Scientific reported a sharp acceleration in its first full year of commercialization, with interim revenue for the six months to 30 June 2026 surging 377.7% year-on-year to RMB64.1 million and gross margin reaching 86.5%. The company subs...
Jenscare Scientific Schedules Board Meeting to Review 2026 Interim Results and Dividend Plan
Aug 19, 2026
Jenscare Scientific Co., Ltd. has scheduled a board meeting for August 31, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The board will also consider whether...
Jenscare forecasts sharp interim revenue surge on heart device growth
Aug 10, 2026
Jenscare Scientific Co., Ltd., a mainland China-based medical device maker specializing in structural heart disease therapies, is seeing strong commercial traction for its Ken-Valve transcatheter aortic valve replacement system and related product...
Jenscare Marks Key Milestone in Global Trial for LuX-Valve Plus
Jul 16, 2026
Jenscare Scientific announced that its proprietary LuX-Valve Plus transvenous tricuspid valve replacement system has successfully completed implantation in the first batch of enrolled subjects in an FDA-approved pivotal registration trial. The dev...
Jenscare Wins EU MDR CE Mark for LuX-Valve Plus, Advancing Global Heart-Device Push
Jul 8, 2026
Jenscare Scientific Co., Ltd. announced that its proprietary transvenous tricuspid valve replacement system, LuX-Valve Plus, has obtained CE certification under the EU Medical Device Regulation, marking a key step in the group’s internationa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.